Toll Free: 1-888-928-9744

Obsessive-Compulsive Disorder - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Obsessive-Compulsive Disorder - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Obsessive-Compulsive Disorder - Pipeline Review, H1 2015', provides an overview of the Obsessive-Compulsive Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Obsessive-Compulsive Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Obsessive-Compulsive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Obsessive-Compulsive Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Obsessive-Compulsive Disorder Overview 7
Therapeutics Development 8
Pipeline Products for Obsessive-Compulsive Disorder - Overview 8
Pipeline Products for Obsessive-Compulsive Disorder - Comparative Analysis 9
Obsessive-Compulsive Disorder - Therapeutics under Development by Companies 10
Obsessive-Compulsive Disorder - Therapeutics under Investigation by Universities/Institutes 11
Obsessive-Compulsive Disorder - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Obsessive-Compulsive Disorder - Products under Development by Companies 16
Obsessive-Compulsive Disorder - Products under Investigation by Universities/Institutes 17
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Addex Therapeutics Ltd 19
C4X Discovery Ltd 20
F. Hoffmann-La Roche Ltd. 21
Heptares Therapeutics Ltd. 22
Novartis AG 23
Omeros Corporation 24
Rottapharm SpA 25
Sellas Inc. 26
Obsessive-Compulsive Disorder - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 34
ADX-71743 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ADX-88178 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bitopertin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CR-5542 Series - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CR-5772 Series - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dipraglurant IR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
fluvoxamine maleate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
mavoglurant - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
methoxycoronaridine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
OMS-527 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
zolpidem tartrate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Obsessive-Compulsive Disorder - Recent Pipeline Updates 51
Obsessive-Compulsive Disorder - Dormant Projects 57
Obsessive-Compulsive Disorder - Discontinued Products 58
Obsessive-Compulsive Disorder - Product Development Milestones 59
Featured News & Press Releases 59
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61
List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, H1 2015 8
Number of Products under Development for Obsessive-Compulsive Disorder - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Comparative Analysis by Unknown Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc., H1 2015 18
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H1 2015 19
Obsessive-Compulsive Disorder - Pipeline by C4X Discovery Ltd, H1 2015 20
Obsessive-Compulsive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 21
Obsessive-Compulsive Disorder - Pipeline by Heptares Therapeutics Ltd., H1 2015 22
Obsessive-Compulsive Disorder - Pipeline by Novartis AG, H1 2015 23
Obsessive-Compulsive Disorder - Pipeline by Omeros Corporation, H1 2015 24
Obsessive-Compulsive Disorder - Pipeline by Rottapharm SpA, H1 2015 25
Obsessive-Compulsive Disorder - Pipeline by Sellas Inc., H1 2015 26
Assessment by Monotherapy Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 33
Obsessive-Compulsive Disorder Therapeutics - Recent Pipeline Updates, H1 2015 51
Obsessive-Compulsive Disorder - Dormant Projects, H1 2015 57
Obsessive-Compulsive Disorder - Discontinued Products, H1 2015 58 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify